BRPI0908398A2 - Uso de lucantona e antimetabólito em combinação, bm como composição e kit farmacêuticos - Google Patents

Uso de lucantona e antimetabólito em combinação, bm como composição e kit farmacêuticos

Info

Publication number
BRPI0908398A2
BRPI0908398A2 BRPI0908398-7A BRPI0908398A BRPI0908398A2 BR PI0908398 A2 BRPI0908398 A2 BR PI0908398A2 BR PI0908398 A BRPI0908398 A BR PI0908398A BR PI0908398 A2 BRPI0908398 A2 BR PI0908398A2
Authority
BR
Brazil
Prior art keywords
lucantone
antimetabolite
kit
combination
pharmaceutical composition
Prior art date
Application number
BRPI0908398-7A
Other languages
English (en)
Inventor
Guru Reddy
Luigi Lenaz
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of BRPI0908398A2 publication Critical patent/BRPI0908398A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0908398-7A 2008-02-29 2009-02-20 Uso de lucantona e antimetabólito em combinação, bm como composição e kit farmacêuticos BRPI0908398A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3283108P 2008-02-29 2008-02-29
PCT/US2009/034629 WO2009108573A1 (en) 2008-02-29 2009-02-20 Combination anti-cancer agents

Publications (1)

Publication Number Publication Date
BRPI0908398A2 true BRPI0908398A2 (pt) 2015-08-11

Family

ID=40566524

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908398-7A BRPI0908398A2 (pt) 2008-02-29 2009-02-20 Uso de lucantona e antimetabólito em combinação, bm como composição e kit farmacêuticos

Country Status (13)

Country Link
US (1) US20090221615A1 (pt)
EP (1) EP2257285A1 (pt)
JP (1) JP5590560B2 (pt)
KR (1) KR20100126453A (pt)
CN (1) CN102014895A (pt)
AU (1) AU2009219464B2 (pt)
BR (1) BRPI0908398A2 (pt)
CA (1) CA2717100A1 (pt)
IL (1) IL207859A (pt)
MX (1) MX2010009502A (pt)
RU (1) RU2516027C2 (pt)
WO (1) WO2009108573A1 (pt)
ZA (1) ZA201006123B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105616402A (zh) * 2010-03-08 2016-06-01 光谱医药公司 治疗癌症的基于噻吨酮的自噬抑制剂疗法
EP2425830A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2023114245A2 (en) * 2021-12-14 2023-06-22 Radin Daniel Pierce Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US6391911B1 (en) * 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
NZ568811A (en) * 2005-12-22 2011-06-30 Astrazeneca Ab Combination of ZD6474 and pemetrexed for treating cancer and the like
BRPI0620118A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente

Also Published As

Publication number Publication date
RU2010139840A (ru) 2012-04-10
AU2009219464B2 (en) 2015-04-09
ZA201006123B (en) 2011-05-25
EP2257285A1 (en) 2010-12-08
AU2009219464A1 (en) 2009-09-03
JP5590560B2 (ja) 2014-09-17
KR20100126453A (ko) 2010-12-01
WO2009108573A1 (en) 2009-09-03
CA2717100A1 (en) 2009-09-03
US20090221615A1 (en) 2009-09-03
JP2011513315A (ja) 2011-04-28
IL207859A0 (en) 2010-12-30
RU2516027C2 (ru) 2014-05-20
CN102014895A (zh) 2011-04-13
IL207859A (en) 2015-09-24
MX2010009502A (es) 2010-11-10

Similar Documents

Publication Publication Date Title
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0920448A2 (pt) compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI1014034A2 (pt) formulação e seu uso, composição, solução injetável e kit.
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0908225A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI1013421A2 (pt) composição parasticida tópica, e, uso de uma composição
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
BRPI0821461A2 (pt) Uso de canabióides em combinação com um medicamento antipsicótico
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0907365A2 (pt) Composição antimicrobiana e uso
FI20086253A (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI1015363A2 (pt) Compostos de quinazolina contendo fósforo, uso dos mesmos, composição e kit

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]